Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00970580
Recruitment Status : Completed
First Posted : September 2, 2009
Last Update Posted : September 16, 2013
Sponsor:
Information provided by:
Biogen

Brief Summary:
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: BIIB022 With Paclitaxel and Carboplatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer
Study Start Date : October 2009
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIIB022 in Combination with Paclitaxel and Carboplatin
BIIB022 in Combination with Paclitaxel and Carboplatin
Drug: BIIB022 With Paclitaxel and Carboplatin
Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
Other Names:
  • Taxol
  • Paraplatin
  • BIIB022
  • Taxane
  • Anti-IGF-1R
  • Cytotoxic
  • Mitotic Inhibitor
  • IGF-1R
  • Alkylating agent




Primary Outcome Measures :
  1. To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >/= 18 years old
  • Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer
  • ECOG Performance Status 0 or 1

Exclusion Criteria:

  • History of another primary cancer within 3 years
  • Any prior or concurrent investigational or standard therapy for treatment of NSCLC
  • Prior anti-IGF-1R therapy
  • Unstable diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00970580


Locations
Layout table for location information
United States, California
Resesarch Site
Los Angeles, California, United States
Resesarch Site
San Diego, California, United States
United States, Colorado
Resesarch Site
Denver, Colorado, United States
Sponsors and Collaborators
Biogen
Layout table for additonal information
Responsible Party: Therese Senta-McMillian, Clinical Team Manager, PRA International
ClinicalTrials.gov Identifier: NCT00970580    
Other Study ID Numbers: 212-LC-101
First Posted: September 2, 2009    Key Record Dates
Last Update Posted: September 16, 2013
Last Verified: November 2011
Keywords provided by Biogen:
BIIB022
Stage IV
Taxol
Stage IIIB
Carboplatin
Paclitaxel
Non Small Cell Lung Cancer
Treatment Naive
Anti IGF1R
NSCLC
Open Label
IGF1R
Paraplatin
Cytotoxic
Mitotic Inhibitor
Taxane
Alkylating agent
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Carboplatin
Alkylating Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action